ProQR Therapeutics Secures $8.1M Funding
Ticker: PRQR · Form: 6-K · Filed: Dec 11, 2024 · CIK: 1612940
| Field | Detail |
|---|---|
| Company | Proqr Therapeutics N.V. (PRQR) |
| Form Type | 6-K |
| Filed Date | Dec 11, 2024 |
| Risk Level | medium |
| Pages | 1 |
| Reading Time | 1 min |
| Key Dollar Amounts | $8.1 Million |
| Sentiment | bullish |
Sentiment: bullish
Topics: funding, rna-editing, press-release
TL;DR
ProQR just got $8.1M from Rett Syndrome Research Trust to boost RNA editing drugs.
AI Summary
On December 11, 2024, ProQR Therapeutics N.V. announced it secured $8.1 million in new funding from the Rett Syndrome Research Trust. This funding is intended to expand their RNA editing programs. The company is a foreign private issuer based in Leiden, The Netherlands.
Why It Matters
This funding injection from the Rett Syndrome Research Trust will accelerate ProQR's development of RNA editing therapies, potentially bringing new treatment options to patients with Rett Syndrome.
Risk Assessment
Risk Level: medium — The company is in the clinical development phase for its therapies, which carries inherent risks associated with drug development and regulatory approval.
Key Numbers
- $8.1M — New Funding (Amount secured from Rett Syndrome Research Trust to expand RNA editing programs.)
Key Players & Entities
- ProQR Therapeutics N.V. (company) — Filer of the 6-K report and recipient of funding.
- Rett Syndrome Research Trust (company) — Provider of new funding.
- $8.1 million (dollar_amount) — Amount of new funding received by ProQR.
- December 11, 2024 (date) — Date of the press release announcing the funding.
FAQ
What is the primary purpose of the $8.1 million funding?
The funding is intended to expand ProQR Therapeutics' RNA editing programs.
Who provided the new funding to ProQR Therapeutics?
The Rett Syndrome Research Trust provided the $8.1 million in new funding.
On what date was the funding announcement made?
The announcement was made on December 11, 2024.
What type of therapies does ProQR Therapeutics focus on?
ProQR Therapeutics focuses on RNA editing therapies.
Where is ProQR Therapeutics N.V. headquartered?
ProQR Therapeutics N.V. is headquartered in Leiden, The Netherlands.
Filing Stats: 275 words · 1 min read · ~1 pages · Grade level 10.2 · Accepted 2024-12-11 07:07:55
Key Financial Figures
- $8.1 Million — ed, “ProQR Therapeutics Announces $8.1 Million in New Funding from Rett Syndrome Resea
Filing Documents
- tm2430675d2_6k.htm (6-K) — 10KB
- tm2430675d2_ex99-1.htm (EX-99.1) — 16KB
- 0001104659-24-127457.txt ( ) — 27KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. PROQR THERAPEUTICS N.V. Date: December 11, 2024 By: /s/ René Beukema René Beukema Chief Corporate Development Officer and General Counsel INDEX TO EXHIBITS Number Description 99.1 Press Release of ProQR Therapeutics N.V. dated December 11, 2024.